slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 220,831-220,860
Pages 10,126
Rows per page 30
Component
220,831-220,860 of 303,780
27
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
29
The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
30
Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
32
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
33
Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
36
Shows two parallel clinical tracks: monotherapy and combination with tislelizumab.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
37
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
40
Includes technical diagrams of the drug construct, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
41
Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
42
Includes detailed scientific diagrams and references to clinical studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
43
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
44
The slide uses a grid-like layout to present headshots, names, titles, and institutional logos for advisory board members.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
45
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
46
The slide is divided into two rows: top row for ImmixBio board members, bottom row for Nexcella board members.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
47
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
48
The slide uses a bar chart to contrast two groups of drugs by their combined annual sales, effectively framing the market size for potential TSTx applications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
49
The slide compares efficacy of Humira, Stelara, and Entyvio against placebo in clinical trials.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
01
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · Attention1 hit
02
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · Attention1 hit
03
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · AttentionLoop · Why Now1 hit
14
The slide explains the revenue decline YoY as a strategic shift in business model (selling components vs full units).Innoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
16
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
18
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · Action1 hit
02
Dense legal text page typical of investor presentations; no charts or visuals.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · Setup1 hit
03
Includes financial strength ratings from AM Best and S&P Global.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · Setup1 hit
04
The slide highlights a CAGR of 5.3% for book value and an average ROE of 13.4% over the period, with a specific callout for the 2020 Nasdaq listing.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · WhyLoop · Benchmark Gap1 hit
05
The chart uses a 2x2 matrix structure to categorize peer performance based on volatility and returns.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · WhyLoop · Benchmark Gap1 hit